Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 28.61 Million SEK | 17.69% |
| 2022 | 24.31 Million SEK | 3.11% |
| 2021 | 23.58 Million SEK | 14.07% |
| 2020 | 20.67 Million SEK | -0.27% |
| 2019 | 20.72 Million SEK | 32.76% |
| 2018 | 15.61 Million SEK | 83.94% |
| 2017 | 8.48 Million SEK | 11.67% |
| 2016 | 7.6 Million SEK | 228.61% |
| 2015 | 2.31 Million SEK | 34.17% |
| 2014 | 1.72 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.96 Million SEK | 1.4% |
| 2024 Q2 | 5.28 Million SEK | -33.72% |
| 2023 Q3 | 5.78 Million SEK | -28.53% |
| 2023 Q4 | 7.85 Million SEK | 35.83% |
| 2023 Q2 | 8.09 Million SEK | 17.85% |
| 2023 FY | 28.61 Million SEK | 17.69% |
| 2023 Q1 | 6.87 Million SEK | -13.31% |
| 2022 Q4 | 7.92 Million SEK | 145.28% |
| 2022 FY | 24.31 Million SEK | 3.11% |
| 2022 Q3 | 3.23 Million SEK | -57.44% |
| 2022 Q2 | 7.59 Million SEK | 36.31% |
| 2022 Q1 | 5.56 Million SEK | -10.94% |
| 2021 Q3 | 5.36 Million SEK | -13.88% |
| 2021 Q4 | 6.25 Million SEK | 16.66% |
| 2021 FY | 23.58 Million SEK | 14.07% |
| 2021 Q1 | 5.74 Million SEK | -2.31% |
| 2021 Q2 | 6.22 Million SEK | 8.38% |
| 2020 Q3 | 5.21 Million SEK | 7.07% |
| 2020 Q4 | 5.87 Million SEK | 12.82% |
| 2020 Q1 | 4.71 Million SEK | -24.53% |
| 2020 FY | 20.67 Million SEK | -0.27% |
| 2020 Q2 | 4.86 Million SEK | 3.2% |
| 2019 Q3 | 4.71 Million SEK | -6.75% |
| 2019 Q4 | 6.24 Million SEK | 32.65% |
| 2019 FY | 20.72 Million SEK | 32.76% |
| 2019 Q1 | 4.71 Million SEK | -4.36% |
| 2019 Q2 | 5.05 Million SEK | 7.12% |
| 2018 Q1 | 2.67 Million SEK | -16.43% |
| 2018 Q4 | 4.93 Million SEK | 33.7% |
| 2018 Q3 | 3.68 Million SEK | -14.61% |
| 2018 Q2 | 4.31 Million SEK | 61.46% |
| 2018 FY | 15.61 Million SEK | 83.94% |
| 2017 Q4 | 3.2 Million SEK | 58.62% |
| 2017 FY | 8.48 Million SEK | 11.67% |
| 2017 Q1 | 1.31 Million SEK | 77.51% |
| 2017 Q2 | 1.96 Million SEK | 49.62% |
| 2017 Q3 | 2.01 Million SEK | 2.96% |
| 2016 Q4 | 738 Thousand SEK | 0.0% |
| 2016 FY | 7.6 Million SEK | 228.61% |
| 2015 FY | 2.31 Million SEK | 34.17% |
| 2014 FY | 1.72 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.681% |
| Ziccum AB (publ) | 27.87 Million SEK | -2.651% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -74.483% |
| BioArctic AB (publ) | 89.62 Million SEK | 68.071% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 32.874% |
| Mendus AB (publ) | 129.13 Million SEK | 77.84% |
| Genovis AB (publ.) | 88.19 Million SEK | 67.553% |
| Intervacc AB (publ) | 79.78 Million SEK | 64.132% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -61.833% |
| Active Biotech AB (publ) | 44.8 Million SEK | 36.136% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 78.944% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 65.592% |
| Aptahem AB (publ) | 10.01 Million SEK | -185.8% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 91.099% |
| Kancera AB (publ) | 63.07 Million SEK | 54.632% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 78.754% |
| Saniona AB (publ) | 1.07 Million SEK | -2557.103% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -294.5% |
| Biovica International AB (publ) | 133.72 Million SEK | 78.6% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -44.603% |
| AcouSort AB (publ) | 25.87 Million SEK | -10.593% |
| Xintela AB (publ) | 57.31 Million SEK | 50.072% |
| Abliva AB (publ) | 27.86 Million SEK | -2.695% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 85.211% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -418.518% |
| OncoZenge AB (publ) | 15.9 Million SEK | -79.925% |
| Amniotics AB (publ) | 29.07 Million SEK | 1.565% |
| 2cureX AB (publ) | 36.51 Million SEK | 21.636% |
| CombiGene AB (publ) | 44.14 Million SEK | 35.174% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -95.298% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.11% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.299% |
| Corline Biomedical AB | 30.16 Million SEK | 5.141% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 50.687% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -293.74% |
| I-Tech AB | 40.14 Million SEK | 28.721% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.67% |
| Cyxone AB (publ) | 28.21 Million SEK | -1.428% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 73.834% |
| Biosergen AB | 26.8 Million SEK | -6.744% |
| Cantargia AB (publ) | 290.01 Million SEK | 90.133% |
| NextCell Pharma AB | -576.01 Thousand SEK | 5068.065% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 84.253% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -1.026% |
| Nanologica AB (publ) | 69.88 Million SEK | 59.052% |
| SynAct Pharma AB | 224.49 Million SEK | 87.253% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 35.22% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -19.465% |
| LIDDS AB (publ) | 27.75 Million SEK | -3.117% |
| Lipum AB (publ) | 37.3 Million SEK | 23.293% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.517% |
| Alzinova AB (publ) | 36.39 Million SEK | 21.373% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 90.123% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -264.257% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 75.131% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -30.701% |
| Simris Alg AB (publ) | 38.64 Million SEK | 25.943% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 79.986% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 91.998% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 74.199% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -94.673% |